Company intelligence / Profile preview

Anixa Biosciences, Inc.

San Jose, California, United Statesanixa.com ↗

Ownership: Public · ANIX
Employees: ~5
Development stage: Phase 1

Overview

The company has two main clinical programs: 1) An ovarian cancer CER-T therapy in Phase 1 trials with Moffitt Cancer Center showing favorable safety profile in the first two cohorts with a notable response in one patient from the first cohort; 2) A preventive breast cancer vaccine in Phase 1 trials with Cleveland Clinic targeting triple-negative breast cancer.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy (specifically CER-T)vaccines
Industry: Biotech

Drug pipeline

10 assets

alpha-lactalbumin

9 more assets in the full pipeline.

Request access →

Partnerships

Moffitt Cancer CenterCleveland Clinic

Financials

Market cap: $93.6M
Total revenue: $0
Enterprise value: $79.9M

Beyond the preview

Go deeper on Anixa Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anixa Biosciences, Inc..

Explore the full profile